POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC PATIENTS RECEIVING LETERMOVIR AS CMV INFECTION PROPHYLAXIS (EBMT 2026) - Feb 7, 2026 - Abstract #B221; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "All patients (100%, 6/6) were treated with Rituximab. CMV prophylaxis with letermovir may increase the risk of severe EBV reactivation. Intensive monitoring of patients receiving letermovir for EBV reactivation is recommended, particularly around 3 months after HSCT, especially in children over 14 years of age."
Clinical • Post-transplantation • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • Pediatrics • Transplantation
|
|
Katarzyna Smalisz1; Anna Zaniewska-Tekieli1; Anna Sarnecka-Paruch1; Magdalena Wozniak1; Aleksandra Krasowska-Kwiecien1; Oktawiusz Wiecha1; Sylwia Bartyzel-Palinska1; Jolanta Gozdzik1
|